Technology
Internet
Real Estate

Rafael Holdings

$14.26
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.29 (2.08%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell RFL and other stocks, options, ETFs, and crypto commission-free!

About

Rafael Holdings, Inc. owns commercial real estate assets and interests in clinical and early stage pharmaceutical companies. It operates through the Real Estate and Pharmaceuticals segments. Read More The Real Estate segment refers to the real estate holdings, including the building at 520 Broad Street in Newark, New Jersey that houses and the company's associated public garage, an office or data center building in Piscataway, New Jersey, and a portion of a building in Israel that hosts offices for IDT and certain affiliates. The Pharmaceuticals segment is comprised of debt interests and warrants in Rafael Pharmaceuticals and a majority equity interest in LipoMedix Pharmaceuticals, research and development, and clinical trials. The company is headquartered in Newark, NJ.

Employees
37
Headquarters
Newark, New Jersey
Founded
Market Cap
194.47M
Price-Earnings Ratio
Dividend Yield
Average Volume
54.73K
High Today
$14.46
Low Today
$13.82
Open Price
$13.91
Volume
7.31K
52 Week High
$19.93
52 Week Low
$3.05

Collections

Technology
Internet
Real Estate
Medical
Pharmaceutical
Data Service
Research And Development
Software Service

News

PR NewswireMar 12

Rafael Holdings Reports Second Quarter Fiscal Year 2019 Results

NEWARK, N.J., March 12, 2019 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE American: RFL), reported revenue of $1.0 million and a loss per share of $0.08 for the second quarter of its 2019 fiscal year, the three months ended January 31, 2019. Highlights Rafael Holdings exercised a warrant and now holds a majority of the outstanding equity of Rafael Pharmaceuticals, Inc., (Rafael Pharma), a clinical stage, metabolic oncology-therapeutics company; Rafael Pharma announced that the European Medicines Agency h...

6

Earnings

-$0.08
-$0.07
-$0.05
-$0.04
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
-$0.08 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.